Inactive Instrument

Cerebain Biotech Corp.

Equities

CBBT

US15672M1062

Biotechnology & Medical Research

Cerebain Biotech Appoints Mustafa Husain to Scientific Advisory Board

January 29, 2015 at 07:30 am

Cerebain Biotech announced that the company has appointed Mustafa Husain, M.D., to its Scientific Advisory Board. Dr. Husain is a preeminent researcher with expertise in device-based research for Neuropsychiatric Disorders. Currently Dr. Husain is Professor of Psychiatry, Neurology & Medicine at Duke University Medical Center and member of Duke Institute for Brain Sciences.

Latest news about Cerebain Biotech Corp.

Diabetes Reversal Group, LLC announced that it has received funding from Cerebain Biotech Corp.	22-09-28	CI
Cerebain Biotech Corp. completed the acquisition of Assets of PKG, Inc.	21-09-19	CI
Cerebain Biotech Corp. entered into a Letter of Intent to acquire Assets of PKG, Inc.	20-08-24	CI
Cerebain Biotech Corp Announces Resignation of Wesley D. Tate as Chief Financial Officer, Chief Operating Officer and as Member of Its Board of Directors	19-07-23	CI
Cerebain Biotech Corp. Reports Earnings Results for the Third Quarter Ended March 31, 2019	19-05-20	CI
Cerebain Biotech Corp. announced that it expects to receive $0.11 million in funding from Auctus Fund Management, LLC	19-03-14	CI
Cerebain Biotech Corp. Reports Earnings Results for the Second Quarter Ended December 31, 2018	19-02-19	CI
Cerebain Biotech Corp. announced that it has received $0.05 million in funding from Jefferson Street Capital LLC	18-12-09	CI
Cerebain Is Considering Multiple Strategic Alternatives	18-12-04	CI
Cerebain Biotech Corp. Auditor Raises 'Going Concern' Doubt	18-09-25	CI
Cerebain Biotech Corp. Auditor Raises 'Going Concern' Doubt	17-09-14	CI
Cerebain Biotech Corp. announced that it has received $0.1 million in funding	17-07-23	CI
Cerebain Biotech Corp. announced that it expects to receive $0.1 million in funding	17-06-28	CI
Cerebain Biotech May Look At Strategic Alternatives	17-03-09	CI
Cerebain Biotech Corp. Auditor Raises 'Going Concern' Doubt	16-09-26	CI
Cerebain Biotech and Mossakowski Medical Research Centre Sign Memorandum of Understanding	16-06-23	CI
Cerebain Biotech Announces Business Relocation into the Heart of Orange County, California	16-05-04	CI
Cerebain Biotech Announces Plans to Seek FDA Approval	16-04-27	CI
Cerebain Biotech Names Azad L. Sheikh to Scientific Advisory Board	16-04-12	CI
Cerebain Biotech Corp. announced that it has received $0.3 million in funding from Geronimo Middle East and Africa	15-06-07	CI
Cerebain Biotech Appoints Mustafa Husain to Scientific Advisory Board	15-01-29	CI
Cerebain Biotech Corp. will Change its Ticker to CBBT from DDOO.D	14-07-18	CI
Discount Dental Materials Inc has Changed its Name to Cerebain Biotech Corp	14-06-20	CI
Cerebain Biotech Corp. has Changed its Ticker to CBBT from DDOO	14-06-19	CI
Discount Dental Materials, Inc. has Changed its Name to Cerebain Biotech Corp	14-06-19	CI

Chart Cerebain Biotech Corp.

Duration

Period

More charts

Company Profile

Cerebain Biotech Corp. is a biomedical company. The Company operates as a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device. The Company, through its subsidiary, Cerebain Operating, Inc., is involved in the discovery of products for the treatment of Alzheimer's disease utilizing Omentum. The Omentum is a layer of tissue lying over internal organs (such as the intestines) and has the ability to generate biological agents that nourish nerves and help them grow. The Company is focused on inclusion of both a medical device solution, as well as a synthetic drug solution in its products. The Company is in the process of preparing for initial clinical trials.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+67.53%	62.86B
IQVIA HOLDINGS INC.	-0.77%	41.38B
LONZA GROUP AG	+45.66%	40.38B
CELLTRION, INC.	-10.72%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.9B
BIO-TECHNE CORPORATION	+4.70%	12.67B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.27B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research